DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438–451

Article  PubMed  Google Scholar 

Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA (2011) Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 26:783–790

Article  PubMed  PubMed Central  Google Scholar 

van de Water W, Kiderlen M, Bastiaannet E, Siesling S, Westendorp RG, van de Velde CJ et al (2014) External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. J Natl Cancer Inst 106:dju051

Article  PubMed  Google Scholar 

Rothwell PM (2005) External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 365:82–93

Article  PubMed  Google Scholar 

Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH et al (2021) Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of breast Cancer specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol 22:e327–e40

Article  PubMed  Google Scholar 

Li J, Huo X, Zhao F, Ren D, Ahmad R, Yuan X et al (2020) Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast Cancer: a systematic review and Meta-analysis. JAMA Netw Open 3:e2020312

Article  PubMed  PubMed Central  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35

Article  CAS  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al (2016) Palbociclib and Letrozole in Advanced breast Cancer. N Engl J Med 375:1925–1936

Article  CAS  PubMed  Google Scholar 

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N et al (2018) Overall survival with Palbociclib and fulvestrant in advanced breast Cancer. N Engl J Med 379:1926–1936

Article  CAS  PubMed  Google Scholar 

Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475–1495

Article  CAS  PubMed  Google Scholar 

Corrigan-Curay J, Sacks L, Woodcock J (2018) Real-world evidence and real-World Data for evaluating Drug Safety and Effectiveness. JAMA 320:867–868

Article  PubMed  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

Article  CAS  PubMed  Google Scholar 

Nilsson G, Hedberg P, Ohrvik J (2014) White blood cell count in elderly is clinically useful in predicting long-term survival. J Aging Res 2014:475093

Article  PubMed  PubMed Central  Google Scholar 

Services USDoHaH (2017) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0

Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol 9:191–192

Article  CAS  PubMed  Google Scholar 

Howie LJ, Singh H, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S et al (2019) Outcomes of older women with hormone Receptor-Positive, human epidermal growth factor receptor-negative metastatic breast Cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis. J Clin Oncol 37:3475–3483

Article  CAS  PubMed  Google Scholar 

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N et al (2018) Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer 101:123–133

Article  CAS  PubMed  Google Scholar 

Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M (2019) Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Res Treat 175:667–674

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gouton E, Tassy L, Micallef J, Meskine A, Sabatier R, Cecile-Herry M et al (2022) The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting. J Cancer Metas Treat. ;8

El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M et al (2021) Palbociclib in combination with aromatase inhibitors in patients >/= 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: a real-world multicentre UK study. Breast 60:199–205

Article  PubMed  PubMed Central  Google Scholar 

Olazagasti C, Lee CS, Liu A, Stefanov D, Cheng K (2023) A deep dive into CDK4/6 inhibitors: evaluating real world toxicities and treatment paradigms in the elderly population. J Oncol Pharm Pract 29:14–21

Article  CAS  PubMed  Google Scholar 

Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C et al (2022) Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open 7:100629

Article  PubMed  PubMed Central  Google Scholar 

Meegdes M, Geurts SME, Erdkamp FLG, Dercksen MW, Vriens B, Aaldering KNA et al (2022) The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: a study of the Dutch SONABRE Registry. Int J Cancer 150:124–131

Article  CAS  PubMed  Google Scholar 

Baltussen JC, de Glas NA, van Holstein Y, van der Elst M, Trompet S, Uit den Boogaard A et al (2023) Chemotherapy-related toxic effects and Quality of Life and Physical Functioning in older patients. JAMA Netw Open 6:e2339116

Article  PubMed  PubMed Central  Google Scholar 

Cardoso Borges F, Alves da Costa F, Ramos A, Ramos C, Bernardo C, Brito C et al (2022) Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: results from a population-based cohort study. Breast 62:135–143

Article  PubMed  PubMed Central  Google Scholar 

Patt D, Liu X, Li B, McRoy L, Layman RM, Brufsky A (2022) Real-world treatment patterns and outcomes of Palbociclib plus an aromatase inhibitor for metastatic breast Cancer: Flatiron Database Analysis. Clin Breast Cancer 22:601–610

Article  CAS  PubMed  Google Scholar 

Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A et al (2020) Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. ESMO Open. ;5

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ et al (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26:1091–1101

Article  CAS  PubMed  Google Scholar 

Wang S, Yang T, Qiang W, Shen A, Zhao Z, Yang H et al (2022) The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis. Support Care Cancer 30:2993–3006

Article  PubMed  Google Scholar 

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D’Hollander K et al (2018) Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol 29:1748–1754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ismail RK, van Breeschoten J, Wouters M, van Dartel M, van der Flier S, Reyners AKL et al (2021) Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast 60:263–271

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L et al (2021) Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res 23:37

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrscher H, Velten M, Leblanc J, Kalish-Weindling M, Fischbach C, Exinger D et al (2020) Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients. Breast Cancer Res Treat 179:371–376

Article  CAS  PubMed  Google Scholar 

Rugo HS, Liu X, Li B, McRoy L, Layman RM, Brufsky A (2023) Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast 69:375–381

Article  PubMed  PubMed Central  Google Scholar 

Caillet P, Pulido M, Brain E, Falandry C, Desmoulins I, Ghebriou D et al (2021) PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation. J Clin Oncol 39:1012

Article  Google Scholar 

Habib MH, Alibhai SMH, Puts M (2024) How representative are participants in geriatric oncology clinical trials? The case of the 5 C RCT in geriatric oncology: a cross-sectional comparison to a geriatric oncology clinic. J Geriatr Oncol 15:101703

Article  CAS